Bio-Techne - TECH Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TECH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TECH, but not buy additional shares or sell existing shares.
View TECH analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 12 month price objectives for Bio-Techne's shares. Their TECH share price forecasts range from $90.00 to $125.00. On average, they anticipate the company's stock price to reach $112.19 in the next twelve months. This suggests a possible upside of 39.1% from the stock's current price.
View analysts price targets for TECH or view top-rated stocks among Wall Street analysts.

Bio-Techne's stock was trading at $129.3350 at the beginning of the year. Since then, TECH shares have decreased by 37.6% and is now trading at $80.67.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our TECH earnings forecast.

Bio-Techne Co. (NASDAQ:TECH) issued its quarterly earnings data on Monday, November, 1st. The biotechnology company reported $0.46 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.03. The biotechnology company had revenue of $257.72 million for the quarter, compared to analysts' expectations of $254.37 million. Bio-Techne had a trailing twelve-month return on equity of 16.37% and a net margin of 26.13%. During the same quarter in the prior year, the business earned $0.29 EPS.

Bio-Techne declared a quarterly dividend on Tuesday, November 1st. Investors of record on Monday, November 14th will be given a dividend of $0.02 per share on Monday, November 28th. This represents a $0.08 dividend on an annualized basis and a yield of 0.10%. The ex-dividend date of this dividend is Thursday, November 10th.
Read our dividend analysis for TECH.

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.39%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 17.93%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 14.04% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

Bio-Techne shares split on the morning of Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly created shares were issued to shareholders after the market closes on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Bio-Techne's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.44%), BlackRock Inc. (11.03%), State Street Corp (4.03%), Neuberger Berman Group LLC (2.64%), Ownership Capital B.V. (1.56%) and Marshall Wace LLP (1.48%). Insiders that own company stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, Harold J Wiens, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends.

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TECH stock can currently be purchased for approximately $80.67.

Bio-Techne (NASDAQ:TECH) has a market capitalization of $12.66 billion and generates $1.11 billion in revenue each year. The biotechnology company earns $272.05 million in net income (profit) each year or $1.7850 on an earnings per share basis.

The company employs 3,000 workers across the globe.

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for the company is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at ir@bio-techne.com, or via fax at 612-656-4400.